格隆汇8月19日丨普门科技(688389.SH)公布，近期收到了1个广东省药品监督管理局颁发的《中华人民 共和国医疗器械注册证（体外诊断试剂）》，产品名称：高敏心肌肌钙蛋白I（hs-cTnISTAT）测定试剂 盒（电化学发光法）。心肌肌钙蛋白I（cTnI）是临床诊断中高度敏感的心肌损伤标志物。当心肌发生 损伤后，细胞中多种形式的心肌肌钙蛋白（包括I-C复合物、I-T-C三聚体以及游离肌钙蛋白I、游离肌钙 蛋白T）释放到血液中，导致外周血中cTnI浓度迅速上升。大量临床研究表明，在急性心肌梗死发病后 4-10小时，心肌肌钙蛋白会出现在血清中，其浓度在12-48小时达到峰值，并在随后4-10天内维持升高状 态。心肌肌钙蛋白水平的动态变化，是鉴别急性和慢性心肌损伤的关键，同时可以辅助诊断心肌梗死。 ...

Company Overview - Pumen Technology specializes in the research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The main products include medical products, home products, testing equipment, and testing reagents [2] Recent Achievements - In January 2024, Pumen Technology was awarded the "Smart Health and Elderly Care Application Pilot Demonstration - Demonstration Enterprise" by three ministries [2] - The project "Micro-tube Inner Surface Wear-resistant Superhydrophobic Coating and Its Application in Medical Devices" won the "2023 China Corrosion and Protection Society Science and Technology Award" first prize [2] - The subsidiary Guangdong Pumen Biomedical Technology Co., Ltd. was recognized as a "Specialized, Refined, Characteristic, and Innovative Small and Medium-sized Enterprise" by the Guangdong Provincial Department of Industry and Information Technology [2] - A collaborative project with Chongqing University on "Key Technology Development and Industrialization of Fully Automatic Specific Protein Analyzer" received the "2023 China Industry-University-Research Cooperation Innovation Achievement Award" second prize [2] Financial Performance - In Q1 2025, the company reported revenue of 215 million yuan, a year-on-year decrease of 29.69% [2] - Net profit for the same period was 53.68 million yuan, down 49.93% year-on-year [2] - The sales gross margin stood at 64.97% [2] Market Position - As of August 15, Pumen Technology's stock closed at 14.68 yuan, with a PE ratio of 21.55, marking a new low in 92 days [1] - The company's total market capitalization is 6.29 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 56.58 and a median of 39.97, Pumen Technology ranks 45th [1][3] Shareholder Information - As of March 31, 2025, Pumen Technology had 13,289 shareholders, an increase of 3,464 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

Group 1 - The core viewpoint of the news highlights the financial performance and market position of Pumen Technology, indicating a decline in revenue and profit for the first quarter of 2025, alongside a relatively low PE ratio compared to the industry average [1][2][3] Group 2 - Pumen Technology's main business includes research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The company achieved a revenue of 215 million yuan in Q1 2025, representing a year-on-year decrease of 29.69%, and a net profit of 53.68 million yuan, down 49.93% year-on-year, with a gross margin of 64.97% [2] - As of March 31, 2025, the number of shareholders increased to 13,289, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - Pumen Technology's current PE ratio is 20.98, while the industry average is 55.76, and the industry median is 39.14, placing the company at the 45th position in the industry ranking [1][3] - The company received several awards, including the "Smart Health Elderly Care Application Pilot Demonstration - Demonstration Enterprise" and the "2023 China Corrosion and Protection Society Science and Technology Award" [2]

Core Insights - The article highlights the development and implementation of a digital health management platform by Guangfa Bank in collaboration with Shenzhen Elderly Care Home, showcasing the bank's commitment to "elderly finance" and its technological and comprehensive financial advantages [1][7]. Group 1: Elderly Finance Development - Guangfa Bank is accelerating the construction of its elderly finance service system, aiming to become a leading account manager in this sector, with a focus on digital transformation and a five-in-one development matrix [2][3]. - The bank has developed over 220 personal pension products to meet diverse customer needs and has established a unique elderly finance service system that addresses the financial service challenges faced by the elderly [3]. Group 2: Digital Health Management Platform - The digital health management platform allows for information sharing among institutions, caregivers, elderly individuals, and their families, enhancing care quality and management efficiency [8]. - The platform integrates various smart devices to monitor health and provides tailored care plans based on health assessments, significantly improving the quality of life for the elderly [8]. Group 3: Collaboration with Healthcare Enterprises - Guangfa Bank focuses on providing financial support to quality projects in the health and elderly care sectors, exemplified by its partnership with Pumen Technology, which has received comprehensive financial solutions to support its growth [4][5]. - The bank has facilitated a collaboration between Pumen Technology and China Life Property Insurance, exploring investment and elderly finance cooperation opportunities [6].

证券代码：688389 证券简称：普门科技 公告编号：2025- 061 深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省药品监督管理 局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》，具体情况如下： 统，对相应校准项目检测时的室内质量控制。 心肌标志物质控品 II 类 粤械注准 2030 年 心肌标志物质控品适用检测项目包括肌钙蛋 白（Myoglobin）、肌酸激酶同工酶（CK-MB）、 N 末端脑利钠肽前体（NT-proBNP）、B 型 利钠肽（BNP）。 二、对公司的影响 一、医疗器械注册证的具体情况 注册 注册证 注册证 产品名称 预期用途 分类 编号 有效期至 适用于经公司配套校准品校准的电化学发光 仪及配套试剂组成的公司电化学发光检测系 本次取得注册证的产品为复合质控品，采用检测样本的标准程序对该质控品进行测定， 将所得结果进行统计分析或与预设参考范围进行比对，判断结果是否处 ...

（文章来源：每日经济新闻） 普门科技8月13日晚间发布公告称，深圳普门科技股份有限公司于近期收到了1个广东省药品监督管理局 颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》。产品名称为"心肌标志物质控品"。 ...

关于自愿披露取得医疗器械注册证的公告 证券代码：688389 证券简称：普门科技 公告编号：2025-061 深圳普门科技股份有限公司 本次取得注册证的产品为复合质控品，采用检测样本的标准程序对该质控品进行测定， 将所得结果进行统计分析或与预设参考范围进行比对，判断结果是否处于参考范围内，以此 确保检测系统的安全、有效。 上述产品注册证的取得，丰富及完善了公司在体外诊断领域的产品品种，有利于进一步 提高公司的产品竞争力和市场拓展能力，对公司未来的经营将产生积极影响。 三、风险提示 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后的实际销售 情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未来业绩的具体影响。 敬请投资者理性投资，注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省药品监督管理 局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》，具体情况如下： | 产品名称 | 注册 | 注册证 | 注册证 | 预 ...

格隆汇8月13日丨普门科技(688389.SH)公布，近期收到了1个广东省药品监督管理局颁发的《中华人民 共和国医疗器械注册证（体外诊断试剂）》，产品名称：心肌标志物质控品。本次取得注册证的产品为 复合质控品，采用检测样本的标准程序对该质控品进行测定，将所得结果进行统计分析或与预设参考范 围进行比对，判断结果是否处于参考范围内，以此确保检测系统的安全、有效。 ...

人民财讯8月13日电，普门科技(688389)8月13日晚间公告，公司近期收到广东省药监局颁发的心肌标志 物质控品《医疗器械注册证(体外诊断试剂)》。该产品适用于经公司配套校准品校准的电化学发光仪及 配套试剂组成的公司电化学发光检测系统，对相应校准项目检测时的室内质量控制。 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Pumen Technology, indicating a significant decline in revenue and profit compared to the previous year [2] - As of August 8, Pumen Technology's stock closed at 14.16 yuan, with a rolling PE ratio of 20.79, marking a new low in 87 days, and a total market capitalization of 6.067 billion yuan [1] - The company ranks 45th in the medical device industry, which has an average PE ratio of 55.70 and a median of 39.08 [1][3] Group 2 - Pumen Technology specializes in the research, manufacturing, global sales, and service of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The company has received multiple awards, including recognition as a "Demonstration Enterprise" in smart health and elderly care, and has won first prize for a project related to medical device applications [2] - The latest quarterly report for Q1 2025 shows a revenue of 215 million yuan, a year-on-year decrease of 29.69%, and a net profit of 53.6847 million yuan, down 49.93%, with a gross margin of 64.97% [2]